5.27

0.57% 0.03

Atara Biotherapeutics Inc (ATRA)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ATRA? Forum Prognose

Schlusskurs vom Vortag:

$5.24

Offen:

$5.27

24-Stunden-Volumen:

76,213

Relative Volume:

0.27

Marktkapitalisierung:

$43.10M

Einnahmen:

$120.77M

Nettoeinkommen (Verlust:

$32.69M

KGV:

1.8081

EPS:

2.9146

Netto-Cashflow:

$-50.94M

1W Leistung:

+13.33%

1M Leistung:

+0.76%

6M Leistung:

-64.42%

1J Leistung:

-14.59%

1-Tages-Spanne:

$5.255

$5.5472

1-Wochen-Bereich:

$4.56

$5.5472

52-Wochen-Spanne:

$3.92

$19.14

Atara Biotherapeutics Inc Stock (ATRA) Company Profile

Firmenname

Atara Biotherapeutics Inc

Sektor

Healthcare (1116)

Branche

Biotechnology (622)

Telefon

805-623-4211

Adresse

1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA

Mitarbeiter

Twitter

@Atarabio

Nächster Verdiensttermin

2026-05-21

Neueste SEC-Einreichungen

ATRA's Discussions on Twitter

Compare ATRA vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ATRA Atara Biotherapeutics Inc	5.27	43.10M	120.77M	32.69M	-50.94M	2.9146
VRTX Vertex Pharmaceuticals Inc	441.20	112.22B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	750.57	79.35B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	849.04	52.80B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	309.66	41.32B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	323.87	35.95B	5.36B	287.73M	924.18M	2.5229

Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-13	Herabstufung	Canaccord Genuity	Buy → Hold
2023-11-09	Herabstufung	Evercore ISI	Outperform → In-line
2023-11-09	Herabstufung	H.C. Wainwright	Buy → Neutral
2023-11-09	Herabstufung	Mizuho	Buy → Neutral
2022-07-20	Herabstufung	Citigroup	Neutral → Sell
2022-07-13	Herabstufung	JP Morgan	Overweight → Neutral
2022-07-13	Herabstufung	Stifel	Buy → Hold
2022-05-10	Herabstufung	Citigroup	Buy → Neutral
2021-05-13	Hochstufung	JP Morgan	Neutral → Overweight
2020-12-09	Herabstufung	Citigroup	Buy → Neutral
2020-12-08	Bestätigt	H.C. Wainwright	Buy
2020-11-10	Bestätigt	H.C. Wainwright	Buy
2020-06-30	Eingeleitet	Evercore ISI	Outperform
2020-06-15	Eingeleitet	H.C. Wainwright	Buy
2020-04-23	Hochstufung	Citigroup	Neutral → Buy
2019-11-08	Herabstufung	JP Morgan	Overweight → Neutral
2019-09-27	Herabstufung	Goldman	Neutral → Sell
2019-09-16	Herabstufung	Jefferies	Buy → Hold
2019-06-04	Hochstufung	Citigroup	Sell → Neutral
2019-05-30	Eingeleitet	ROTH Capital	Buy
2019-05-23	Eingeleitet	Stifel	Buy
2019-01-23	Eingeleitet	Mizuho	Buy
2018-04-10	Eingeleitet	JP Morgan	Overweight
2018-03-16	Eingeleitet	Guggenheim	Neutral
2018-03-05	Bestätigt	Jefferies	Buy
2018-02-28	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2018-02-15	Herabstufung	Citigroup	Neutral → Sell
2018-01-03	Hochstufung	Citigroup	Sell → Neutral
2017-10-06	Fortgesetzt	Goldman	Neutral

Alle ansehen

Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten

Apr 18, 2026

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Atara - GlobeNewswire

Apr 18, 2026

Apr 17, 2026

REMINDER: Atara Biotherapeutics, Inc. Investors With Significant Losses Must Act By May 22, 2026 – Contact Kirby McInerney LLP - Business Wire

Apr 17, 2026

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile

Apr 17, 2026

Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit - GlobeNewswire

Apr 17, 2026

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire

Apr 17, 2026

ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 17, 2026

ATRA Shareholder Alert: May 22, 2026 Lead Plaintiff Deadline in Atara Biotherapeutics, Inc. Securities Class Action Lawsuit — The Gross Law Firm - GlobeNewswire Inc.

Apr 17, 2026

Apr 16, 2026

ATRA Stockholders Have RightsIf You Lost Money Investing in Atara Biotherapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses - PR Newswire

Apr 16, 2026

Atara Biotherapeutics Faces Securities Lawsuit After FDA Setbacks and Sharp Stock Declines Tied to Tabelecleucel - TipRanks

Apr 16, 2026

Bronstein, Gewirtz & Grossman LLC Urges Atara - GlobeNewswire

Apr 16, 2026

ATRA INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds - GuruFocus

Apr 16, 2026

Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain OfficersATRA - ChartMill

Apr 16, 2026

ATRA INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - ChartMill

Apr 16, 2026

2026-04-16 | ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:ATRA | Press Release - Stockhouse

Apr 16, 2026

Apr 15, 2026

ROSEN, A LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel ... - Caledonian Record

Apr 15, 2026

ROSEN, A LEADING LAW FIRM, Encourages Atara - GlobeNewswire

Apr 15, 2026

DEADLINE ALERT for LU, ATRA, and COTY: The Law Offices of - GlobeNewswire

Apr 15, 2026

ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 15, 2026

Apr 14, 2026

Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA - ChartMill

Apr 14, 2026

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit - Lelezard

Apr 14, 2026

ATRA Shareholder Alert: May 22, 2026 Lead Plaintiff Deadline in Atara Biotherapeutics, Inc. Securities Class Action Lawsuit — The Gross Law Firm - Morningstar

Apr 14, 2026

Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire

Apr 14, 2026

2026-04-14 | ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:ATRA | Press Release - Stockhouse

Apr 14, 2026

ATRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 14, 2026

Apr 13, 2026

Class Action Filed Against Atara Biotherapeutics Over Alleged Securities Fraud - National Today

Apr 13, 2026

Class Action Filed Against Atara Biotherapeutics, Inc. (ATRA) Seeking Recovery for Investors – Contact Levi & Korsinsky - GlobeNewswire

Apr 13, 2026

Atara Biotherapeutics Faces Securities Fraud Lawsuit - National Today

Apr 13, 2026

Activity Recap: Is Atara Biotherapeutics Inc impacted by rising ratesMarket Trend Summary & Verified Technical Signals - baoquankhu1.vn

Apr 13, 2026

Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) - GlobeNewswire

Apr 13, 2026

Portnoy Law Firm Announces Class Action on Behalf of Atara Biotherapeutics, Inc. Investors - WFMZ.com

Apr 13, 2026

Buybacks Report: What are analysts price targets for Atara Biotherapeutics IncInsider Selling & Precise Trade Entry Recommendations - baoquankhu1.vn

Apr 13, 2026

Atara Biotherapeutics, Inc.Common Stock (NQ: ATRA - The Chronicle-Journal

Apr 13, 2026

Apr 12, 2026

ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 12, 2026

ROSEN, A TOP RANKED LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors with Losses in ... - Bluefield Daily Telegraph

Apr 12, 2026

ROSEN, A TOP RANKED LAW FIRM, Encourages Atara - GlobeNewswire

Apr 12, 2026

2026-04-12 | ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:ATRA | Press Release - Stockhouse

Apr 12, 2026

Apr 10, 2026